Table 6.

Evaluation data of optimized SNEDDS formulation subjected to stability studies at 40 ± 2°C/75 ± 5% RH.

Sampling points (days)	% drug content	t 90% (min⁡)	% transmittance
0	98.88 ± 1.53	<10	81.43
30	98.31 ± 1.86	<10	82.03
60	97.86 ± 2.32	<10	82.31
90	97.41 ± 2.82	<10	82.28